Results 31 to 40 of about 12,722 (192)

Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Sacubitril/valsartan improves health outcomes for heart failure with reduced ejection fraction relative to angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, but it carries higher out‐of‐pocket costs. Neither the impact
Birju R. Rao, Candace D. Speight, Larry A. Allen, Scott D. Halpern, Yi‐An Ko, Daniel D. Matlock, Miranda A. Moore, Alanna A. Morris, Laura D. Scherer, Mary C. Thomson, Peter Ubel, Neal W. Dickert   +11 more
doaj   +1 more source

Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2018
Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs.
Abraham, Andersen, Anker, Anker, Borer, Ghosh, Greenberg, Lin, McMurray, McMurray, Metcalfe, Neaton, Packer, Rogers, Rogers, Rogers, Rogers, Solomon, Wei   +18 more
core   +3 more sources

EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS

Рациональная фармакотерапия в кардиологии, 2017
Aim. To study the effect of sacubitril/valsartan compared with valsartan on natriuresis, diuresis, blood pressure (BP) and the level of biomarkers in hypertensive patients.Material and methods.
Zh. D. Kobalava, S. V. Villevalde, I. A. Meray, O. I. Lukina   +3 more
doaj   +1 more source

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction

Cardiac Failure Review, 2021
Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has become a milestone in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) in the last decade.
Mauro Gori, James L Januzzi, Emilia D’Elia, Ferdinando L Lorini, Michele Senni   +4 more
doaj   +1 more source

Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization [PDF]

, 2016
Background: Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. Objectives: This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates ...
Claggett, Brian L., Desai, Akshay S., Lefkowitz, Martin, McMurray, John J.V., Packer, Milton, Rouleau, Jean L., Shi, Victor, Solomon, Scott D., Starling, Randall, Swedberg, Karl, Teerlink, John, Zile, Michael R.   +11 more
core   +2 more sources

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]

, 2017
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Aichner, Solveig, Albrecht, Diego, Bremerich, Jens, Delles, Christian, Freyhardt, Patrick, Heye, Tobias, Hrabak-Paar, Maja, Janka, Rolf, Keicher, Christian, Khder, Yasser, Langenickel, Thomas, Mayr, Michael, Ott, Christian, Schmieder, Roland E., Wagner, Frank, Yates, Denise   +15 more
core   +1 more source

The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review

Journal of Cardiovascular Pharmacology and Therapeutics, 2022
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF.
Rui Zhang MD, PhD, Xiaotong Sun PhD, Ya Li MD, PhD, Wenzheng He MM, Hongguang Zhu MD, PhD, Baoshan Liu MD, PhD, Aiyuan Zhang MD, PhD   +6 more
doaj   +1 more source

Sex Differences in the Effectiveness of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril–Valsartan for the Treatment of Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background PARAGON‐HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) suggested a potential benefit of sacubitril–valsartan in women with preserved ejection ...
Zahra N. Sohani, Hassan Behlouli, Cristiano Soares de Moura, Michal Abrahamowicz, Louise Pilote   +4 more
doaj   +1 more source

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation

International Journal of Cardiology: Heart & Vasculature, 2019
Background: Sacubitril/valsartan has been shown to improve mortality and reduce hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF).
Geoffrey Bayard, Antoine Da Costa, Romain Pierrard, Cécile Roméyer-Bouchard, Jean Baptiste Guichard, Karl Isaaz   +5 more
doaj   +1 more source